03.1 / One continuum
Prevention work begins with individual analysis of the available relevant findings, exposures and clinical context, followed by a structured profile. Biological mechanisms and modifiable risk are then examined while keeping population evidence, individual uncertainty and clinical outcomes distinct.
Conceptual examples · no patient assessment or treatment recommendation
Prevention aims to lower the probability of developing cancer; it cannot establish that an individual will remain cancer-free. Population estimates of preventable disease describe a burden under specified assumptions, not a personal percentage reduction or a promise. Curetanics’ research approach is to organize context-dependent hypotheses and evidence gaps. Neither a computational model nor a favorable biological signal guarantees prevention.
Cancer can arise through inherited changes, errors during cell division and damage associated with environmental exposures. Their contributions vary by tissue and cancer type. Age, family history, prior exposures and modifiable behaviors should therefore remain separate information layers. A context model must avoid implying that a diagnosis reflects personal failure or that changing one factor removes every other source of risk.
Authoritative prevention recommendations prioritize established measures such as avoiding tobacco, physical activity and appropriate dietary patterns; vaccination against relevant cancer-causing infections belongs to broader prevention practice. WCRF advises against using supplements for cancer prevention. Research into bioactive mechanisms does not override those recommendations. Nutrient-deficiency treatment is a separate clinical question and should not be relabeled as proof that a supplement prevents cancer.
A change in oxidative stress, inflammation or gene expression can motivate a research hypothesis without demonstrating lower cancer incidence. Its interpretation depends on experimental system, concentration, duration and tissue relevance. Observational associations can reflect confounding or reverse causation. A defensible workflow preserves those limits, compares competing explanations and seeks appropriately designed human studies with meaningful outcomes and sufficiently long follow-up.
The randomized ATBC trial found no lung-cancer prevention benefit from the tested vitamin supplements in male smokers and identified increased lung-cancer incidence with beta-carotene. This is a warning about extrapolation from nutritional associations to isolated supplemental compounds. It does not mean that every formulation or population has the same effect. Safety, exposure, population and clinical endpoints must be evaluated for the specific proposed use.
Screening tests asymptomatic people for disease or precursors; early diagnosis addresses people with symptoms. Some screening pathways can also prevent cancers by finding removable precancerous lesions, but not all screening tests prevent cancer. A research platform must not replace recommended screening or clinical assessment. Any proposed prevention application needs a defined population, time horizon, comparator, harms assessment and independently evaluated outcomes.
Sources describe research methods, prevention or supportive care. They do not establish Curetanics-specific efficacy. Source titles remain in their original language.